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Abstract
The European Commission has requested EFSA to assess animal diseases according to the criteria as
laid down in Articles 5, 7, 8 and Annex IV for the purpose of categorisation of diseases in accordance
with Article 9 of the Regulation (EU) No 2016/429 (Animal Health Law). This scientiﬁc opinion
addresses the ad hoc method developed for assessing any animal disease for the listing and
categorisation of diseases within the Animal Health Law (AHL) framework. The assessment of individual
diseases is addressed in distinct scientiﬁc opinions that are published separately. The assessment of
Articles 5, 8 and 9 criteria is performed on the basis of the information collected according to Article 7
criteria. For that purpose, Article 7 criteria were structured into parameters and the information was
collected at parameter level. The resulting fact sheets on the proﬁle and impact of each disease were
compiled by disease scientists. A mapping was developed to identify which parameters from Article 7
were needed to inform each Article 5, 8 and 9 criterion. Speciﬁcally, for Articles 5 and 9 criteria, a
categorical assessment was performed, by applying an expert judgement procedure, based on the
mapped information. The judgement was performed by EFSA Panel experts on Animal Health and
Welfare in two rounds, individual and collective judgement. The output of the expert judgement on the
criteria of Articles 5 and 9 for each disease is composed by the categorical answer, and for the
questions where no consensus was reached, the different supporting views are reported.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Article 5 of the Regulation (EU) No 429/20161 of the European Parliament and of the Council on
transmissible animal diseases (Animal Health Law), hereinafter referred as AHL, provides the list of
animal diseases to which the rules set out in the AHL apply. These rules include the categorisation of
those diseases into different groups depending on the appropriate measures, as provided for in Article
9 of that Regulation.
In addition to the list of ﬁve signiﬁcant diseases laid down in Article 5 (1) of the AHL, there is a list
of other diseases in Annex II that is amendable by the Commission by means of a delegated act.
Furthermore, there are transmissible animal diseases for which certain control or trade measures
apply today but are not included in the mentioned Annex II and diseases that might be relevant for
forthcoming Union intervention.
Criteria for listing of animal diseases are laid down in Article 5(3), for the assessment in Article 7
and for the categorisation of animal diseases in Annex IV of the AHL.
Those criteria constitute the benchmarks for the exercises of listing and categorisation and for
determining the disease prevention and control rules to be applied to the different categories of listed
diseases.
Furthermore, Article 8 of the AHL envisages that disease speciﬁc rules for listed diseases apply to
listed animal species. Those species, or groups of animal species, are those that are either susceptible
species or they have the capability to carry speciﬁc diseases.
Speciﬁc criteria for listing of species are provided for in Article 8(3) of the AHL.
The Commission needs a scientiﬁc advice to enable the assessment of the following diseases within
the framework of the listing and categorisation according to the AHL, although the same methodology
could be applied in the future for further request:
1) Aujeszky’s disease
2) Enzootic bovine leukosis (EBL)
3) Bovine viral diarrhoea (BVD)
4) Infectious bovine rhinotracheitis (IBR)
5) Porcine reproductive and respiratory syndrome (PRRS)
6) Paratuberculosis
7) Koi herpes virus disease (KHV)
8) Anthrax
9) Infection with Brucella abortus, Brucella melitensis and Brucella suis
10) Japanese encephalitis
11) West Nile fever
12) Trypanosoma evansi infections (including Surra)
13) Equine encephalomyelitis (eastern and western)
14) Venezuelan equine encephalomyelitis
15) Borna disease
16) Bovine tuberculosis
17) Infection with low pathogenic avian inﬂuenza virus
18) Avian mycoplasmosis (Mycoplasma gallisepticum, Mycoplasma meleagridis)
19) Salmonella infection in poultry with serotypes of animal health relevance (Salmonella
Pullorum, Salmonella Gallinarum and Salmonella arizonae)
20) Ebola
21) Bluetongue (all serotypes or group of serotypes)
22) Bovine genital campylobacteriosis
23) Trichomonosis
24) Border disease
25) Ovine epididymitis (Brucella ovis)
26) Contagious bovine pleuropneumonia
27) Contagious caprine pleuropneumonia
1 Regulation (EC) No 429/2016 of the European Parliament and of the Council of 9 March 2016 on transmissible animal diseases
and amending and repealing certain acts in the area of animal health (‘Animal Health Law’). OJ L 84, 31.3.2016, p. 1–208.
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28) Infestation with Varroa spp. (Varroosis)
29) Batrachochytrium salamandrivorans (Bsal).
The criteria, provided in the Appendix A of this opinion, shall be used as a basis for the analytical
assessment. The risk manager needs an updated scientiﬁc advice in order to:
• assess if the above mentioned animal diseases are diseases for which control measures at the
European Union (EU) level are justiﬁed;
• proceed proﬁling each disease with a view to its categorisation;
• assign listed species to the diseases identiﬁed as relevant for the EU intervention.
In view of the above, and in accordance with Article 29 of Regulation (EC) No 178/2002, the
Commission asks EFSA for a scientiﬁc opinion:
1) ToR 1: for each of the diseases an assessment, following the criteria laid down in Article 7 of the
AHL, on its eligibility to be listed for Union intervention as laid down in Article 5(3) of the AHL.
2) ToR 2: for each of those diseases which was found eligible to be listed for Union intervention:
a) an assessment of its compliance with each of the criteria in Annex IV to the AHL for the
purpose of categorisation of diseases in accordance with Article 9 of the AHL;
b) a list of animal species that should be considered candidates for listing in accordance with
Article 8 of the AHL.
1.2. Interpretation of the Terms of Reference (ToR)
An assessment of the animal diseases listed in Section 1.1 according to the criteria of Articles 5,
Annex IV for the purpose of categorisation of diseases in accordance with Article 92 and 8 of the AHL
is requested by the European Commission in ﬁve similar mandates, to be done on the basis of the
information available according to the assessment criteria of Article 7 (proﬁle and impact). The criteria
of Articles 5, 7, 8 and 9, are provided in the Appendix A of the present opinion.
The ﬁrst ToR requires an assessment of each disease against the eligibility criteria as listed in Article 5.
The Article 5 of the Regulation (EU) No 429/2016 provides the list of animal diseases to which the rules set
out in the AHL apply. A disease is eligible to be listed if it has been assessed according to the criteria listed in
Article 7 and if it meets the criteria of Article 5 of the AHL. The criteria of Article 7 concern the disease
proﬁle, impact of the disease, potential to generate a crisis situation and its potential for use in bioterrorism,
the feasibility, availability, effectiveness and the impact of disease prevention and control measures.
The second ToR requires an assessment of each disease against the criteria as in Annex IV of the
AHL for the purpose of categorisation of diseases in accordance with Article 9. These criteria provide
the rules for the categorisation of the diseases into different groups depending on the appropriate
measures (eradication, control, etc.), as provided for in Article 9 of the AHL. There are ﬁve categories
in Article 9 of the AHL, each with a deﬁned purpose as follows:
• category A: listed diseases that do not normally occur in the Union and for which immediate
eradication measures must be taken as soon as they are detected.
• category B: listed diseases which must be controlled in all Member States with the goal of
eradicating them throughout the Union.
• category C: listed diseases which are of relevance to some Member States and for which
measures are needed to prevent them from spreading to parts of the Union that are ofﬁcially
disease-free or that have eradication programmes for the listed disease concerned.
• category D: listed diseases for which measures are needed to prevent them from spreading on
account of their entry into the Union or movements between Member States.
• category E: listed diseases for which there is a need for surveillance within the Union.
Each category foresees the application of certain disease prevention and control rules to the
respective listed diseases when the disease in question fulﬁls the criteria laid down in the relevant
Section of Annex IV of AHL (Sections 1–5 which correspond to categories A–E, respectively).
The same ToR requires the provision of the list of animal species that should be considered
candidates for listing in accordance with Article 8(3). This Article envisages that speciﬁc rules for listed
2 In the opinion the ‘criteria of Annex IV for the purpose of categorisation of diseases in accordance with Article 9’ are indicated
as ‘Article 9 criteria’.
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diseases apply to listed animal species. Those species, or groups of animal species, are those that are
either susceptible species or those that have the capability to carry speciﬁc pathogenic agents.
For the ﬁrst ToR, the disease and impact proﬁle following Article 7 criteria requires compilation for
each disease. This represents the baseline information for the assessment as requested by ToR 1 and
ToR 2, i.e. to enable determination of the eligibility for listing the disease in the AHL, the category into
which each of the diseases ﬁts according to Article 9 of AHL, and the animal species that should be
considered as relevant for that disease.
The use and the purpose of the assessment for the European Commission should be to provide
clear and robust information to qualify the importance of each disease in the Union, and if justiﬁed,
which measures should be taken in the EU.
The answer to the mandates will be structured in one document providing the description of the
methodology for the assessment of diseases and an individual document providing the information and
assessment for each disease.
2. Data and methodologies
In order to address the ToRs as provided by the Commission, an ad hoc method of assessment has
been developed and used for each disease for collecting information on the proﬁle and impacts of the
targeted diseases and conducting the assessment of the disease within the framework of AHL.
The framework used to elaborate the method for information collection and assessment of diseases
are the criteria laid down in Articles 5, 7, 8(3) and 9 of the AHL as provided to EFSA and as reported in
the Appendix A of the present opinion.
The AHL foresees that the assessment of each disease, based on the criteria listed in Articles 5
(eligibility for listing), 9 (categorisation into control classes) and 8 (listing species) should be performed
on the basis of the information collected according to Article 7 (disease proﬁle and impacts). Accordingly,
the proposed and developed method consists of three main steps as summarised in the following Table 1:
These steps are described in detail in the following sections.
Table 1: Assessment steps
ToR Section Main steps Description Result
1 2.1 Data collection for
disease proﬁle and
impacts based on
Article 7
Structuring
Article 7
criteria into
parameters
Transcription of Article 7
criteria to allow data
collection
Fact sheet of the
disease proﬁle and
impacts
Disease
Fact sheet
compilation
Disease scientist recruited
to collect data and
compile Fact sheet
1 2.2 Use of Article 7
data for disease
assessment based
on Articles 5, 8
and 9
Article 5 based
on Article 7
Mapping each Article 5
criterion as a function of
Article 7 criteria
Article 5 by Article 7
matrix
2 Article 9 based
on Article 7
Mapping each Article 9
criterion as a function of
Article 7 criteria
Article 9 by Article 7
matrix
Article 8 based
on Article 7
Mapping each Article 8
criterion as a function of
Article 7 criteria
Assessment of
candidate animal
species for listing
(Article 8 by Article 7
matrix)
1 & 2 2.3 Disease
assessment
Expert
selection
AHAW Panel members for
expert judgement
Disease assessment
for listing and
categorisationAssessment
method
Implementation of a two
rounds approach
(individual
judgement + collective
behavioural aggregation)
on the basis of
Sections 2.1 and 2.2
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2.1. Data collection for disease proﬁle and impacts based on Article 7
criteria
In order to compile the information on (a) the diseases proﬁle, (b, c) the impact of the diseases,
(d) the availability, feasibility and effectiveness of control measures, and (e) the impact of disease
prevention and control measures according to Article 7 of AHL,
• the Article 7 criteria (in Appendix A) are broken down and structured into parameters;
• data/information is collected at parameter level by selected disease scientists and drafted in a
fact sheet format.
2.1.1. Restructuring of Article 7 criteria into parameters
For each criterion in Article 7 of the AHL, subcriteria are identiﬁed on which information is needed
to fully characterise the disease. For each subcriterion, a list of parameters characterising the sub-
criterion and related parameters are deﬁned by the working group (WG) experts. Existing frameworks
on disease and impact assessment using a multi criteria approach are consulted in order to support
the deﬁnition and identiﬁcation of appropriate parameters to assess diseases according to Article 7
criteria of the AHL (DEFRA, 2006; RIVM, 2006; WHO, 2006; European Commission, 2007; ETPGAH,
2007; Council of the European Union, 2008; Krause et al., 2008; Cardoen et al., 2009; Havelaar et al.,
2010; OIE, 2010; Del Rio Vilas et al., 2011; ECDC, 2011; DISCONTOOLS, 2012; EFSA BIOHAZ
Panel (2012); FAO, 2012; Humblet et al., 2012; Ng and Sargeant, 2012; Cox et al., 2013; Del Rio Vilas
et al., 2013; Ng and Sargeant, 2013; ECDC, 2015; Gao et al., 2015; McFadden et al., 2016; Ng and
Sargeant, 2016). The result of the restructuring of Article 7 is shown in Table 2.
Concerning the criteria e(i) and e(ii), i.e. the impact of disease prevention and control measures as
regards the costs for affected sectors and the economy as a whole, and the societal acceptance,
respectively, an assessment of all direct and indirect costs cannot be provided in this opinion in a
general framework, since the analysis of costs of control measures and of their societal acceptance is
not science-driven but it is linked to the different socioeconomical contexts and to the different
management decisions to be applied. In order to assess this criterion, a description is provided about
the elements characterising the costs for the affected sectors and the types of prevention and control
measures that may entail issues about societal acceptance, by bringing some cases studies, where
available.
Regarding the criterion about impact of disease prevention and control measures as regards
environment and biodiversity, the outcomes of interest concern the use and potential residues of
biocides and medical treatments and reference to already available environmental risk assessment is
provided where available.
The evidence collected on the different criteria is summarised in narrative and in summary tables.
2.1.2. Disease fact sheet compilation
Disease fact sheet
A disease fact sheet is deﬁned as a document containing all relevant information on a speciﬁc
disease following the structure of the Article 7 criteria of the AHL. The aim is to draft a comprehensive,
succinct and up to date fact sheet on the proﬁle, impact, and control options of each disease
requested by the mandate. The fact sheet covers all criteria of Article 7 of the AHL according to the
parameters as mentioned above.
The fact sheet is used as scientiﬁc basis to allow the EFSA panel of experts on animal health and
welfare to assess the criteria for listing and categorisation of a certain disease in the framework of AHL
(Articles 5 and 9 of AHL), and for the identiﬁcation of the animal species concerned (Article 8 of the
AHL).
Disease Scientist
The disease fact sheet compilation has been outsourced to disease scientists (DSs). A DS is a
scientist who has the expertise to retrieve, extract, collate and interpret relevant scientiﬁc information
related to a speciﬁc disease, covering all AHL (Article 7) criteria and related parameters.
The required expertise of the DS should cover the criteria on the disease proﬁle as laid down in
Article 7 of the AHL, which are listed below:
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• Epidemiology
• Economics of animal health and production
• Ecology/ecosystems/dependencies/impact on
The above listed ﬁelds of expertise, deemed to be necessary, implies also certain knowledge on the
following domains:
• Clinical expression
• Diagnostic methods
• Disease control strategies
• Monitoring/surveillance strategies
• Pharmacology
• Risk assessment
• Statistics
• Zoology
The expertise of a candidate DS is expected to cover most of the required ﬁelds for at least one of
the diseases that EFSA is requested to assess.
DSs with the required scientiﬁc proﬁle have been identiﬁed and selected by a search in databases
of scientiﬁc literature, by giving priority to authors of the most recent publications and reviews and by
considering scientists working in the OIE, EU or national reference laboratories.
In this speciﬁc case of the AHL disease proﬁling, the search string for retrieving the relevant
literature had to be general enough to cover all aspects of each disease. The search string used is the
following:
[name of the disease] OR [name of the pathogen] OR [acronym of the disease] OR [acronym of
the pathogen] OR [common name of the disease]
Once the list of authors is returned by the search, the selection of the DS among the potential
candidates, as described above, is based on number of publications, date of publication, afﬁliation and
availability.
Fact sheet compilation
Sources of information:
The DS could use scientiﬁc literature as sources of information, giving priority to peer-reviewed
literature and based on the evidence pyramid, where most reliance can be given to systematic reviews
and meta-analyses, followed by critically-appraised topics with syntheses, critically-appraised articles
(synopses), randomised controlled trials, cohort studies, case–control studies, case-series and reports,
and expert opinions. Least reliance can be given to the latter. Furthermore, the following sources of
information could be used:
• EFSA databases (Data Collection Framework and/or ad hoc databases)
• EFSA scientiﬁc outputs published on the same topic (Scientiﬁc Opinions, Scientiﬁc Reports,
Technical Reports, other outputs)
• EMA outputs relevant for treatments and vaccination
• ECDC outputs relevant for the zoonotic aspects
• EUROSTAT for information related to trade
• Information by MSs
• OIE manuals and any other output relevant for the diagnostic tests and the vaccines
The DS should also identify for which Article 7 criteria and related parameters the data and the
information available, at the time of the fact sheet compilation, are lacking or not up to date. The data
and the information should be combined and narratively described, interpreted and commented,
following the structure of the fact sheet. The DS should complete and update each of them by
reporting in detail the sources of information used.
Completed fact sheets are then reviewed by two independent experts selected from the EFSA
Panel on Animal Health and Welfare (AHAW) experts or from the EFSA ad hoc WG, whose role is to
assess the integrity of the documents. The reviewers assess that the content of the fact sheets
sufﬁciently covers what is requested by the parameters of Article 7, and highlighted any knowledge
gap, any missing or wrong information, any missing critical or relevant references and possible
expert bias introduced by the DS. The comments provided by reviewers are addressed and endorsed
by DSs.
Assessment of animal diseases based on AHL criteria
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2.2. Use of Article 7 criteria and parameters to inform Articles 5, 8 and 9
criteria: mapping
As mentioned, the assessment of each disease, based on the criteria listed in Article 5 (eligibility for
listing), should be performed on the basis of the information collected according to Article 7. For this
purpose, a mapping is developed to identify which elements from Article 7 are needed to inform each
Article 5 criterion. The table based on Article 7 criteria at parameter level (disease fact sheet) is used
to build a matrix linking sets of relevant Article 7 parameters to each relevant criterion of Article 5.
Likewise, the assessment of the diseases in view of their categorisation based on Article 9, and of
animal species that should be considered candidates for listing in accordance with Article 8 of the AHL
are performed on the basis of the information collected under Article 7. In the same way, a similar
mapping is developed to build a matrix linking sets of relevant Article 7 parameters to each relevant
criterion of Article 9 and Article 8. For Article 8, the mapped Article 7 information constitutes directly
the outcome of the assessment.
2.3. Disease assessment according to Article 5 and Article 9
The assessment of each disease according to Articles 5 and 9 criteria is carried out using the
procedure of expert judgement that involves expert selection and judgement as described below.
2.3.1. Expert selection
The AHAW Panel is composed of 21 members who have been selected according to their expertise
on animal health and welfare, and their absence of conﬂict of interest has been screened according to
the EFSA rules on declarations of interest for the experts.3 Furthermore, the AHAW Panel adopts and is
the author of the EFSA opinions according to Article 29 of the Regulation (EC) No 178/20024. For this
reason, the AHAW Panel is the group of experts considered as the most entitled to perform such a
judgement. Accordingly, a group of at least 10 experts from the AHAW Panel are requested to
participate to the expert judgement.
2.3.2. Assessment method
Expert judgement is performed using the Individual and Collective Behavioural Aggregation (ICBA)
approach described below. Experts are individually provided with the disease fact sheet prior to the
judgement together with interpretations and deﬁnitions of some wording used in Articles 5 and 9.
The criteria of Articles 5 and 9 are phrased in a way that they could be translated into questions to
which Yes/No answers could be given (fulﬁlment check). In order to facilitate the risk managers’
decision for listing and categorisation, a Yes/No/na (na: ‘not available’, meaning insufﬁcient evidence or
irrelevant to judge) assessment for the criteria of Articles 5 and 9 was developed. Accordingly, an
assessment table is constructed, where a mapping of Article 5 and 9 in relation to Article 7, with the
possible Yes/No/na outcomes, is displayed.
Using that assessment table, the experts indicate their Y/N or ‘na’ judgement on each criterion of
Articles 5 and 9, and they may provide the different reasoning arguments supporting their judgement.
The ICBA method to perform the expert judgement for each disease is implemented in two rounds:
Round 1: Individual judgement
Each expert performs his/her individual judgement. On the basis of the evidence collected from
Article 7 criteria/parameters and mapped into Article 5 and Article 9 criteria, the experts are asked
individually to provide categorical answers (Y/N/na) (using Table 2 and Appendix B). For questions
where no consensus is reached at the individual level, the experts are requested to provide the view/
reasoning leading them to the ﬁnal Y/N/na answer.
Round 2: Collective judgement
The collective judgement consists of a behavioural aggregation where the individual judgements
produced in Round 1 are discussed in a physical meeting, where additional material/information may
be supplied by the experts present, in order to seek for consensus. Following the discussion, for each
3 http://www.efsa.europa.eu/en/howwework/doi
4 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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Article 5 and 9 criterion, the ﬁnal answer is provided (consensus for Yes, No or ‘na’ or no consensus)
together with the supporting views where the consensus is not reached. The following are taken into
account:
• only the responses from experts having taken part in both individual and collective judgement
are counted per question in the ﬁnal output;
• the questions where full consensus is reached during the individual judgement are not further
discussed in the physical meeting.
The overall output of the judgement achieved for each Article 5 and 9 criterion for each disease is
composed by a categorical answer (Y/N/na), and for the no consensus questions, the outcome
includes all the supporting views and the %Y, %N and %na.
Fact sheet amendment: following the individual judgment, and during the collective judgment until
the ﬁnal adoption, additional information or clariﬁcation of certain points can be added into the fact
sheet for consideration. The fact sheet can also be revised when necessary.
Reassessment: In the case of substantial changes in the fact sheet that can impact the outcome of
the assessment already done, the target question has to be reassessed under collective judgment (not
necessarily involving the same judges).
3. Results
The main objective of this work is to develop an ad hoc methodological approach ﬁt for the
purpose of assessing each disease under rules prescribed in the AHL. As a result, the method that has
been developed consists in three chronological main steps as summarised in Figure 1 and described
below.
The three processes in Figure 1 are described in detail in the following Sections 3.1, 3.2 and 3.3.
Figure 1: Flow chart of the algorithm for the assessment of diseases within the AHL framework
according to the ad-hoc method developed in this opinion
Assessment of animal diseases based on AHL criteria
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3.1. Collection of information
At the commencement of the assessment of any disease, a disease scientist (DS) is selected as
described in Section 2. The DS is provided with a template of a fact sheet to be completed following
the framework determined from the structured Article 7 (input) (see Table 2). The result of breaking
down the Article 7 criteria of the AHL into sub-criteria and parameters is given below in Table 2.
The DS collects information and drafts the disease fact sheet according to the criteria they have
been provided (structured Article 7 criteria of the AHL).
The disease fact sheet is then reviewed by two independent reviewers (AHAW Panel experts or WG
experts) and DS endorses the comments provided.
Input: Structured Article 7 (Table 2).
Output: Disease proﬁle and impacts in a fact sheet format (Result for ToR 1).
Assessment of animal diseases based on AHL criteria
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3.2. Mapping of Article 7 criteria in relation to Article 5, Article 9 and
Article 8 criteria
The disease fact sheet as in step 1 (structured table of Article 7 criteria) is reorganised using
mapping matrices that allow assigning each set of information related to each Article 7 criteria (and
related parameters) to the relevant Articles 5, 9 and 8 criteria. The mapping matrices providing each
criterion of Articles 5, 9 and 8 as a function of Article 7 criteria (and related parameters) are given
below in Tables 3, 4 and 5, respectively.
As a result, the disease fact sheet is reshaped into disease assessment table, an example is shown
in Table 6 where the ﬁrst question of Article 5 is reported, while, in Appendix B, the tables for all other
questions are reported.
Output: Mapping matrices (Tables 3, 4 and 5) and a disease assessment table (Table 6). For Article
8, mapping of the disease fact sheet into Table 5 provides directly the outcome of the assessment.
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In Appendix B, the instructions for the judgement including deﬁnitions and interpretations of terms
and questions are provided.
3.3. Disease assessment
The disease assessment is performed using the ICBA approach as described in Section 2 on
methodology. In the ﬁrst round of judgement, the disease assessment table (Table 6) in step 2 is
provided to experts (AHAW panel experts) for individual assessment of the disease. In the second
round of judgement, the results of the expert judgement obtained in ﬁrst round are used for the
collective behavioural aggregation.
The ﬁnal result of the expert judgement on each criterion of article 5 and article 9 is the output of
the collective judgement, which combines the outcome of the individual judgements, their discussion
and any additional relevant material known to the experts participating in the judgement. The ﬁnal
outcome can be revised by the AHAW Panel on the basis of any new available evidence before the
adoption of the scientiﬁc opinion, and the judgment can be amended accordingly. The result of
assessment is reported in Tables 7 and 8.
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria indicated in point A and at least one criterion as in point B of Article 5(3) (see
Appendix A.2). Likewise, a disease is considered to belong or classiﬁed in a category according to
Article 9 if it fulﬁls all criteria indicated at points a and b and at least one of the criteria indicated at
Table 5: Mapping matrix of criteria for listing the animal species or group of animal species affected
or that pose a risk for the spread of a speciﬁc disease as in Article 8 of the AHL vs Article
7 parameters
Article 8 criteria for listing Mapped Article 7 criteria
3(a) Animal species or group of animal species
are susceptible to a speciﬁc disease
or scientiﬁc evidence indicates that
such susceptibility is likely
(a)(i) Animal species concerned by the disease
(a)(v) Persistence of the disease (i.e. infective agent)
in an animal population or in the environment*
3(b) Animal species or group of animal
species are vector species or reservoirs
for that disease, or scientiﬁc evidence
indicates that such role is likely
(a)(i) Animal species concerned by the disease
(a)(vi) The routes of transmission of the disease
between animals and, when relevant,
between animals and humans**
*: Parameters used in the mapping are from 1 to 3.
**: Mapped at subparameter level.
Table 6: Example of disease assessment table
Question A(i) scientiﬁc evidence indicates that the disease is transmissible
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(vi) The routes and speed
of transmission of the
disease between animals
and, when relevant,
between animals and
humans
(a)(vi) 1 Type of routes of transmission
from animal to animal (horizontal, vertical)
<Information from the fact sheet>
(a)(vi) 2 Type of routes of transmission
from animal to humans (direct, indirect)
<Information from the fact sheet>
Table 7: Final result of the expert judgement on each criterion of Article 5 or Article 9.
Question Final outcome
A(i) Is the disease is transmissible? Y/N
NC
na
Colour code: green = consensus (Yes/No), yellow = no consensus (NC), red = not available (na), i.e. insufﬁcient evidence or
irrelevant to judge (na).
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points c, d, e as in Annex IV (see Appendix A.3). According to the assessment methodology, a criterion
is considered fulﬁlled when the outcome is ‘Yes’.
For each outcome without consensus, an additional table (Table 8) is provided followed by the
detailed list of different supporting views.
For each disease, the ﬁnal results of the assessment according to the assessment steps as shown in
Figure 1 are the following:
• Disease fact sheet: provides information on the disease proﬁle and impacts. The format is
shown in Table 2.
• Disease assessment according to Article 5: it provides information on the eligibility of the
disease to be listed. The format is shown in Tables 6 and 7.
• Disease assessment according to Article 9: it provides information on the compliance of the
disease with each of the criteria in Annex IV to the AHL for the purpose of categorisation in
accordance with Article 9. The format is shown in Tables 6 and 7.
• Disease assessment according to article 8: a list of animal species that should be considered
candidates for listing in accordance with Article 8 of the AHL, based on the criteria as displayed
in Table 5 of the present document.
The assessment results are drafted in a separated opinion, one for each disease.
Conclusions
• An ad hoc method for disease listing and categorisation according to the framework of Articles
7, 5 and Annex IV in accordance with Articles 9 and 8 of the AHL has been developed in order
to allow the AHAW Panel to perform the requested assessment on each disease.
• The assessment methodology includes: (i) the procedure for collecting the data and compiling
the information in a disease fact sheet, (ii) the mapping matrices of Articles 5, 9 and 8 based
on Article 7 providing the directions for use of the relevant information from the disease fact
sheets, and (iii) the expert judgement for the disease assessment for listing and categorisation.
• This methodology is used for the following assessment steps: the assessment according to the
Article 7 criteria (disease fact sheet); the expert judgement according to Articles 5 and 9
criteria; and the assessment according to Article 8 criteria on the species concerned by the
disease, which is derived from the related criteria of the fact sheet.
• The expert judgement approach that was followed during the disease assessment combines
the individual and collective knowledge and opinion of experts and seeks consensus, when
possible.
• This method has been developed and adapted to a set of predeﬁned and prestructured criteria
from the legislative text of the AHL. Therefore, the structure of the method follows the
legislative texts of the AHL. Initially, data are collected on the disease proﬁle and impacts
according to Article 7, next, the eligibility of the disease for listing is assessed and categorised
according to Articles 5 and 9, respectively, and ﬁnally the animal species candidates for listing
are assessed according to Article 8.
• Finally, the assessment framework as proposed above (see Figure 1) does not target nor
exclude a formal and automated procedure.
Table 8: Final result of the expert judgement in case of no consensus (NC) outcome for each
criterion of Article 5 or Article 9.
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(v) Disease has or could have a signiﬁcant
negative impact on the environment, including
biodiversity, of the Union (Example question)
NC % of Yes % of No % of na
NC: no consensus.
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Glossary and Abbreviations
AHL Animal health law
AHAW EFSA Panel on Animal Health and Welfare
CITES Convention on International Trade in Endangered Species of Wild Fauna
and Flora
Disease fact sheet A document containing all relevant information on a speciﬁc disease.
The framework of the document follows the structure of the Article 7
criteria of the new AHL
Disease scientist (DS) A scientist who is able to retrieve, extract, collate and interpret relevant
scientiﬁc information related to a speciﬁc disease, covering all domains
required to address the AHL (Article 7) criteria and related parameters
DIVA Differentiating Infected from Vaccinated Animals (vaccine)
ICBA Individual and collective behavioural aggregation
IUCN International Union for Conservation of Nature
MSs Member States
OIE World Organisation for Animal Health
OIE/CFSPH The Center for Food Security and Public Health (OIE Collaborating Centre
for Day-One Veterinary Competencies and Continuing Education)
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Appendix A – Criteria of Articles 7, 5, 8 and Annex IV for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL
A.1. Article 7 – Assessment parameters
The Commission shall use the following assessment parameters in order to determine whether a
disease meets the conditions requiring it to be listed in accordance with Article 5(2):
a) the disease proﬁle, which shall comprise the following:
i) the animal species concerned by the disease;
ii) the morbidity and mortality rates of the disease in animal populations;
iii) the zoonotic character of the disease;
iv) the resistance to treatments, including antimicrobial resistance;
v) the persistence of the disease in an animal population or in the environment;
vi) the routes and speed of transmission of the disease between animals and, when
relevant, between animals and humans;
vii) the absence or presence and distribution of the disease in the Union, and, where the
disease is not present in the Union, the risk of its introduction into the Union;
viii) the existence of diagnostic and disease control tools;
b) the impact of the disease on:
i) agricultural and aquaculture production and other parts of the economy, as regards:
 the level of presence of the disease in the Union;
 the loss of production due to the disease;
 other losses;
ii) human health, as regards:
 transmissibility between animals and humans;
 transmissibility between humans;
 the severity of human forms of the disease;
 the availability of effective prevention or medical treatment in humans;
iii) animal welfare;
iv) biodiversity and the environment;
c) its potential to generate a crisis situation and its potential use in bioterrorism;
d) the feasibility, availability and effectiveness of the following disease prevention and control
measures:
i) diagnostic tools and capacities;
ii) vaccination;
iii) medical treatments;
iv) biosecurity measures;
v) restrictions on the movement of animals and products;
vi) killing of animals;
vii) disposal of carcasses and other relevant animal by-products;
e) the impact of disease prevention and control measures, as regards:
i) the direct and indirect costs for the affected sectors and the economy as a whole;
ii) their societal acceptance;
iii) the welfare of affected subpopulations of kept and wild animals;
iv) the environment and biodiversity.
A.2. Article 5 – Criteria for listing of diseases
1. The disease-speciﬁc rules for the prevention and control of diseases provided for in this
Regulation shall apply to:
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a) the following listed diseases:
i) foot and mouth disease;
ii) classical swine fever;
iii) African swine fever;
iv) highly pathogenic avian inﬂuenza;
v) African horse sickness; and
b) the listed diseases set out in the list in Annex II.
2. The Commission shall adopt delegated acts in accordance with Article 264 concerning
amendments to the list referred to in point (b) of paragraph 1 of this Article.
3. A disease shall be included on the list referred to in point (b) of paragraph 1 of this Article if it
has been assessed in accordance with Article 7 and it meets:
a) all of the following criteria:
i) scientiﬁc evidence indicates that the disease is transmissible;
ii) animal species are either susceptible to the disease or vectors and reservoirs thereof
exist in the Union;
iii) the disease causes negative effects on animal health or poses a risk to public health
due to its zoonotic character;
iv) diagnostic tools are available for the disease; and
v) risk-mitigating measures and, where relevant, surveillance of the disease are effective
and proportionate to the risks posed by the disease in the Union; and
b) at least one of the following criteria:
i) the disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character;
ii) the disease agent has developed resistance to treatments which poses a signiﬁcant
danger to public and/or animal health in the Union;
iii) the disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union;
iv) the disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism; or
v) the disease has or could have a signiﬁcant negative impact on the environment,
including biodiversity, of the Union.
4. The Commission shall adopt delegated acts in accordance with Article 264 concerning the
removal of a disease from the list referred to in point (b) of paragraph 1 of this Article when that
disease no longer fulﬁls the criteria provided for in paragraph 3 of this Article.
5. The Commission shall review the listing of each disease in the light of newly available signiﬁcant
scientiﬁc data.
A.3. Annex IV – Criteria for the application of the disease prevention
and control rules referred to in Article 9(1) to diseases listed in
accordance with Article 5
The scope of this Annex is to detail the criteria to be considered by the Commission when
determining the disease prevention and control rules to be applied to the different categories of
diseases listed in accordance with Article 5.
The process of categorisation shall take into account the proﬁle of the disease in question, the level
of the impact of that disease on animal and public health, animal welfare and the economy, and the
availability, feasibility and effectiveness of the diagnostic tools and different sets of disease prevention
and control measures provided for in this Regulation with respect to the disease.
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A.3.1. Section 1 Criteria for the application of the disease prevention
and control rules referred to in point (a) of Article 9(1)
The diseases for which the disease prevention and control rules referred to in point (a) of Article 9
(1) apply shall be considered to have the most severe animal health, public health, economic, social or
environmental impacts on the Union. Those diseases need to fulﬁl the following criteria:
a) the disease in question is: and
i) not present in the territory of the Union;
ii) present only in exceptional cases (irregular introductions); or
iii) present in only in a very limited part of the territory of the Union;
b) the disease in question is highly transmissible; in addition to direct and indirect transmission,
there may also be possibilities of airborne, waterborne or vector-borne spread. The disease
may affect multiple species of kept and wild animals, or a single species of kept animals of
economic importance, and may result in high morbidity and signiﬁcant mortality rates.
In addition to the criteria set out in points (a) and (b), those diseases need to fulﬁl one or more of
the following criteria:
c) the disease in question has a zoonotic potential with signiﬁcant consequences for public
health, including epidemic or pandemic potential or possible signiﬁcant threats to food safety;
d) the disease in question has a signiﬁcant impact on the economy of the Union, causing
substantial costs, mainly related to its direct impact on the health and productivity of animals;
e) the disease in question has a signiﬁcant impact on one or more of the following:
i) society, with in particular an impact on labour markets;
ii) animal welfare, by causing suffering to large numbers of animals;
iii) the environment, due to the direct impact of the disease or due to the measures taken
to control it;
iv) in the long term, biodiversity or the protection of endangered species or breeds,
including the possible disappearance of, or long-term damage to, those species or
breeds.
A.3.2. Section 2 Criteria for the application of the disease prevention
and control rules referred to in point (b) of Article 9(1)
The diseases for which the disease prevention and control rules referred to in point (b) of Article 9
(1) apply shall be controlled in all Member States with the goal of eradicating them throughout the
Union.
Those diseases need to fulﬁl the following criteria:
a) the disease in question is endemic in nature and is present in the whole or part of the Union
territory. However, several Member States or zones of the Union are free of the disease; and
b) the disease is moderately to highly transmissible; in addition to direct and indirect
transmission, there may also be possibilities of airborne, waterborne or vector-borne spread.
It may affect single or multiple animal species and may result in high morbidity, with in
general low mortality.
In addition to the criteria set out in points (a) and (b), those diseases need to fulﬁl one or more of
the following criteria:
c) the disease in question has a zoonotic potential with signiﬁcant consequences for public
health, including epidemic potential or possible signiﬁcant threats to food safety;
d) the disease in question has a signiﬁcant impact on the economy of the Union causing
substantial costs, mainly related to its direct impact on the health and productivity of animals;
e) the disease has a signiﬁcant impact on one or more of the following:
i) society, with in particular an impact on labour markets;
ii) animal welfare, by causing suffering to large numbers of animals;
iii) the environment, due to the direct impact of the disease or due to the measures taken
to control it;
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iv) in the long term, biodiversity or the protection of endangered species or breeds,
including the possible disappearance of, or long-term damage to, those species or
breeds.
A disease to which the measures referred to in point (a) of Article 9(1) apply, which has not been
successfully and promptly eradicated in a part of the Union, and has, in that part of the Union,
obtained an endemic character, may be subject to disease prevention and control measures under
point (b) of Article 9(1), in that part of the Union.
A.3.3. Section 3 Criteria for the application of the disease prevention
and control rules referred to in point (c) of Article 9(1)
The diseases for which the disease prevention and control rules referred to in point (c) of Article 9
(1) apply are of relevance to some Member States and measures are needed to prevent them from
spreading to parts of the Union that are ofﬁcially disease-free or that have eradication programmes for
the listed disease in question.
Those diseases need to fulﬁl the following criteria:
a) in terrestrial animals, the disease in question is endemic in nature and is present in the whole
or part of the Union territory; or in aquatic animals, several Member States or zones of the
Union are free of the disease; and
b) i) in terrestrial animals, the disease in question is moderately to highly transmissible, mainly
through direct and indirect transmission. The disease mainly affects multiple or single
animal species, usually does not result in high morbidity, and has a negligible or no
mortality rate. Often the most observed effect is production loss;
ii) in aquatic animals, the disease is moderately to highly transmissible, mainly through direct
and indirect transmission. The disease affects multiple or single animal species and may
result in high morbidity and usually low mortality. Often the most observed effect is
production loss.
In addition to the criteria set out in points (a) and (b), those diseases need to fulﬁl one or more of
the following criteria:
c) the disease in question has a zoonotic potential with signiﬁcant consequences for public
health, or possible threats to food safety;
d) the disease in question has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems.
e) the disease in question has a signiﬁcant impact on one or more of the following:
i) society, with, in particular, an impact on labour markets;
ii) animal welfare, by causing suffering to large numbers of animals;
iii) the environment, due to the direct impact of the disease or of the measures taken to
control it;
iv) in the long term, biodiversity or the protection of endangered species or breeds,
including the possible disappearance of, or long-term damage to, those species or
breeds.
A.3.4. Section 4 Criteria for the application of the disease prevention
and control rules referred to in point (d) of Article 9(1)
The disease prevention and control rules referred to in point (d) of Article 9(1) shall apply to
diseases that fulﬁl the criteria set out in Sections 1, 2 or 3 and to other diseases fulﬁlling the criteria
set out in Section 5 where the risk posed by the disease in question can be effectively and
proportionately mitigated by measures concerning movements of animals and products in order to
prevent or limit its occurrence and spread.
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A.3.5. Section 5 Criteria for the application of the disease prevention
and control rules referred to in point (e) of Article 9(1)
The disease prevention and control rules referred to in point (e) of Article 9(1) shall apply to
diseases that fulﬁl the criteria set out in Sections 1, 2 or 3 and to other diseases where surveillance of
the disease is necessary for reasons relating to animal health, animal welfare, human health, the
economy, society or the environment.
A.4. Article 8 – Listed species
Animal species or groups of animal species shall be added to the list if they are affected or if they
pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible to a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely.
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Appendix B – Expert Judgement document
Here below the instructions for the judgement and, where needed, the interpretations of the
questions is reported.
B.1. Instructions
All evidence provided by question should be read and considered when answering the question.
Sequence of the task for judging:
1) read the question, including any internal interpretation of this question
2) read the information/data
3) answer the question.
B.2. Interpretation of terms and questions
The following interpretations were considered for the assessment of criteria of Article 5 for listing
and of Annex IV referring to categories of Article 9 of the AHL:
Interpretation of the term ‘signiﬁcant’ when it is used in relation to the impact or the effect of
the disease or of the disease control or preventive measure on animal health, public health, economy,
society, environment:
A disease will be considered as having a signiﬁcant impact on a system (animal health, public
health, society, environment, economic) when it causes overall additional effects (damages, losses,
costs, disturbance, . . .) compared to the situation in the absence of the disease either,
• at local scale (a single country for EU) but with long-term (> 1 year) effects
• at larger scale (> 2 countries) regardless the effect duration (short or long-terms)
or that require mitigation and control (authority) actions to restoring the system in its state in the
absence of the disease.
Interpretation of questions in Article 5 B(i), B(iii) – ‘The disease causes or could cause
. . .effect/impact. . .’ and B(v) – ‘The disease has or could have. . .impact. . .’:
• the disease impact or negative effects have to be assessed without considering any effect of
interventions or control measures that are (if the disease is already present in the EU) or can
be put in place (if the disease is exotic and assuming it is introduced into the EU).
All Article 9 criteria/questions refer to the EU regardless ‘in the Union’ is mentioned or not in
the question.
Interpretation of questions in Article 9 2.4A, 2.4B – ‘The disease may result in high
morbidity. . .’:
• For the judgment of this question, the potential for the disease to have high morbidity and/or
high mortality even in absence of control measures are considered.
Interpretation of questions in Article 9 4AB, 4C, 5A, 5B, 5C, 5D starting with ‘the disease
has a signiﬁcant impact on. . .’:
• Case 1: if the disease is not present (exotic) or present only in exceptional cases, or only in a
very limited part of EU:
 Potential impact: Use the fact sheet and collective opinion to assess the impact of the
disease assuming it is introduced into the EU and without considering the effects of any
interventions or control measures.
• Case 2: if the disease is endemic/present in the whole or part of the Union
 Current impact: Use the fact sheet (which provides information of the current status) and
collective opinion to assess the impact of the disease by taking into account the effects of
the interventions or control measures that are in place (if any);
 Potential impact: when relevant, assess the impact of the disease considering the potential
situation in EU as the interventions or control measures in place (if any) would be removed.
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For the disease related to case 2 the different type of impact (current and potential, as explained
above), is assessed separately in the table collecting the answers of the judges or explained in the
reasoning points.
Interpretation of question D in Article 9 ‘the risk posed by the disease in question can be
effectively and proportionately mitigated by measures concerning movements of animals and products
in order to prevent or limit its occurrence and spread’: for exotic diseases, the assessment of the
effectiveness of movement of animals and products to mitigate the risk should take into account also
the control of movements into the EU (import checks).
For questions related to Article 9
The following interpretations were used for the assessment of the criteria across the categories A,
B and C. If criterion 1 about disease distribution is fulﬁlled in category B, then the same available data
would most likely also support fulﬁllment of category. For criterion 2.1 about transmissibility, the
options in category B and C are the same. The criterion 2.2 is the same in category A and B, thus with
same outcome. The criterion 2.3 in category B and C is considered always fulﬁlled, because a disease
is dealt here if it affects at least one animal species. Criteria 5(a-d) are the same in category A, B and
C and have the same outcome. The evidence extrapolated from the relevant criteria of Article 7 (fact
sheet) should always support such interpretation.
B.3. Information provided to the experts for performing the
assessment on each disease: information mapping
Here below all the example tables are reported, which show the criteria (questions) of Articles 5
and 9 next to the related criteria and parameters of Art. 7, based on which the judgement on each
question should be performed.
B.3.1. Article 5
Question A(i)
Question A(i) scientiﬁc evidence indicate that the disease is transmissible
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(vi) The routes and speed of
transmission of the disease
between animals and, when
relevant, between animals and
humans
(a)(vi) 1 type of routes of transmission
from animal to animal (horizontal,
vertical)
<Information from the fact sheet>
(a)(vi) 2 type of routes of transmission
from animal to humans (direct, indirect)
<Information from the fact sheet>
Question A(ii)
Question A(ii) animal species are either susceptible to the disease or vectors and reservoirs
thereof exist in the Union
Interpretation- indicate if animal species susceptible to the disease or vector or reservoir are present in the Union
Answer Y ☐ N ☐ na ☐
Article 7
criteria
Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(i) Animal
species
concerned by
the disease
(a)(i) 1 naturally susceptible wildlife species
(or families/orders)
<Information from the fact sheet>
(a)(i) 2 naturally susceptible domestic species
(or families/orders)
<Information from the fact sheet>
(a)(i) 3 experimentally susceptible wildlife species
(or families/orders)
<Information from the fact sheet>
(a)(i) 4 experimentally susceptible domestic species
(or families/orders)
(a)(i) 5 wild reservoir species (or families/orders) <Information from the fact sheet>
(a)(i) 6 domestic reservoir species (or families/orders) <Information from the fact sheet>
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Question A(iii)
Question A(iii) disease causes negative effects on animal health OR poses a risk to public health
due to its zoonotic character
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(ii) Morbidity and mortality
rates of the disease in animal
populations
(a)(ii) 1 Prevalence/incidence <Information from the fact sheet>
(a)(ii) 2 Case-morbidity rate (% clinically
diseased animals out of infected ones)
<Information from the fact sheet>
(a)(ii) 3 Case-fatality rate <Information from the fact sheet>
(a)(iii) Zoonotic character of
the disease
(a)(iii) 1 report of zoonotic human cases <Information from the fact sheet>
(a)(iv) Resistance to
treatments, including
antimicrobial resistance
(a)(iv) 1 resistant strain to any treatment
even at laboratory level
<Information from the fact sheet>
(b)(ii) Impact of the disease
on human health
(b)(ii) 1 type of routes of transmission
between animals and humans - see a(vi)2
<Information from the fact sheet>
(b)(ii) 2 Incidence of zoonotic cases
(b)(ii) 3 Occasional or substantial?
(b)(ii) 4 Epidemic or pandemic?
(b)(ii) 5 DALY
(b)(iii) Impact of the disease
on animal welfare
(b)(iii) 1 severity of clinical signs at case
level and related level and duration of
impairment
<Information from the fact sheet>
(c) Potential to generate a
crisis situation and its
potential use in bioterrorism
(c) 1 listed in OIE/CFSPH classiﬁcation
of pathogens
<Information from the fact sheet>
(c) 2 listed in the Encyclopedia of
Bioterrorism Defense of Australia Group
<Information from the fact sheet>
(c) 3 included in any other list of
potential bio- agro-terrorism agents
Question A(iv)
Question A(iv) diagnostic tools are available for the disease
Interpretation- diagnostic tools are available for the disease in the Union
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(viii) Existence of
diagnostic and disease
control tools
(a)(viii) 1 Existence of diagnostic tools <Information from the fact sheet>
(a)(viii) 2 Existence of disease control tools <Information from the fact sheet>
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Question A(v)
Question 5 A(v) the risk-mitigating measures and, where relevant, surveillance of the disease are
effective and proportionate to the risks posed by the disease in the Union
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(viii) Existence of
diagnostic and disease
control tools
(a)(viii) 1 Existence of diagnostic tools <Information from the fact sheet>
(a)(viii) 2 Existence of disease control tools <Information from the fact sheet>
(b)(ii) Impact of the disease
on human health
(b)(ii) 7 Availability of medical treatment
and their effectiveness (therapeutic effect
and any resistance)
<Information from the fact sheet>
(b)(ii) 8 Availability of vaccines and their
effectiveness (reduced morbidity)
(d)(i) Feasibility, availability
and effectiveness of
diagnostic tools and
capacities
(d)(i) 1 ofﬁcially/internationally recognised
diagnostic tool, OIE certiﬁed
<Information from the fact sheet>
(d)(i) 2 Se and Sp of diagnostic test <Information from the fact sheet>
(d)(i) 3 type of sample matrix to be tested
(blood, tissue, etc.)
<Information from the fact sheet>
(d)(ii) Feasibility, availability
and effectiveness of
vaccination
(d)(ii) 1 types of vaccines available on the
market
<Information from the fact sheet>
(d)(ii) 2 availability/production capacity
(per year)
<Information from the fact sheet>
(d)(ii) 3 Field protection as reduced
morbidity (reduced susceptibility to infection
and/or to disease)
<Information from the fact sheet>
(d)(ii) 4 Duration of protection <Information from the fact sheet>
(d)(ii) 5 Way of administration <Information from the fact sheet>
(d)(iii) Feasibility, availability
and effectiveness of medical
treatments
(d)(iii) 1 types of drugs available on the
market and/or allowed by the EU regulatory
system
<Information from the fact sheet>
(d)(iii) 2 availability/production capacity
(per year)
<Information from the fact sheet>
(d)(iii) 3 therapeutic effect in the ﬁeld
(effectiveness)
(d)(iii) 4 Way of administration
(d)(iv) Feasibility, availability
and effectiveness of
biosecurity measures
(d)(iv) 1 available biosecurity measures <Information from the fact sheet>
(d)(iv) 2 effectiveness of biosecurity
measure (description)
<Information from the fact sheet>
(d)(iv) 3 feasibility of biosecurity measure
(description)
<Information from the fact sheet>
(d)(v) Feasibility, availability
and effectiveness of
restrictions on the
movement of animals and
products, as control measure
(d)(v) 1 available restriction movement
measures
<Information from the fact sheet>
(d)(v) 2 effectiveness of restriction of
animal movement in preventing the
between farm spread (description)
<Information from the fact sheet>
(d)(v) 3 feasibility of restriction of animal
movement (description)
<Information from the fact sheet>
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Question 5 A(v) the risk-mitigating measures and, where relevant, surveillance of the disease are
effective and proportionate to the risks posed by the disease in the Union
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(d)(vi) Feasibility, availability
and effectiveness of killing of
animals
(d)(vi) 1 available killing of animal measures <Information from the fact sheet>
(d)(vi) 2 effectiveness of killing animals (at
farm level or within the farm) for reducing/
stopping spread of the disease (description)
<Information from the fact sheet>
(d)(vi) 3 feasibility of killing animals
(description)
<Information from the fact sheet>
(d)(vii) feasibility, availability
and Effectiveness of disposal
of carcasses and other
relevant animal by-products
(d)(vii) 1 disposal options available <Information from the fact sheet>
(d)(vii) 2 effectiveness of disposal option
(description)
<Information from the fact sheet>
(d)(vii) 3 feasibility of disposal option
(description)
<Information from the fact sheet>
Question B(i)
Question B(ii)
Question 5 B(i) disease causes or could cause signiﬁcant negative effects in the Union on animal
health, OR poses or could pose a signiﬁcant risk to public health due to its zoonotic character?
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(ii) Morbidity and mortality
rates of the disease in animal
populations
(a)(ii) 1 Prevalence/Incidence <Information from the fact sheet>
(a)(ii) 2 Case-morbidity rate
(% clinically diseased animals
out of infected ones)
<Information from the fact sheet>
(a)(ii) 3 Case-fatality rate <Information from the fact sheet>
(a)(iii) Zoonotic character of
the disease
(a)(iii) 1 report of zoonotic human cases <Information from the fact sheet>
(a)(iv) Resistance to
treatments, including
antimicrobial resistance
(a)(iv) 1 resistant strain to any treatment
even at laboratory level
<Information from the fact sheet>
(b)(ii) Impact of the disease
on Human health
(b)(ii) 1 type of routes of transmission
between animals and humans - see a(vi)2
<Information from the fact sheet>
(b)(ii) 2 Incidence of zoonotic cases <Information from the fact sheet>
(b)(ii) 3 Occasional or substantial? <Information from the fact sheet>
(b)(ii) 4 Epidemic or pandemic? <Information from the fact sheet>
(b)(ii) 5 DALY <Information from the fact sheet>
Question B(ii) disease agent has developed resistance to treatments WHICH poses a signiﬁcant
danger to public and/or animal health in the Union?
Interpretation- disease agent has developed resistance to treatments AND therefore poses a signiﬁcant danger
to public and/or animal health. If no treatment exists the answer should be na
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(iv) Resistance to
treatments, including
antimicrobial resistance
(a)(iv)1 list of any resistant strain to any
treatment even at laboratory level
<Information from the fact sheet>
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Question B(iii)
Question B(iv)
Question B(v)
Question B(iii) disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union?
Interpretation- disease and/or infection causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union if no intervention is in place
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(ii) Morbidity and mortality rates
of the disease in animal populations
(a)(ii) 3 Case-fatality rate <Information from the fact sheet>
(b)(i) The impact of the disease on
agricultural and aquaculture
production and other parts of the
economy
(b)(i) 1 Number of MSs where the
disease is presence
<Information from the fact sheet>
(b)(i) 2 Proportion of production
losses (%) by epidemic/endemic
situation (milk, growth, semen,
meat, etc.. . .)
<Information from the fact sheet>
Question B(iv) disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(c) potential to generate a crisis
situation and its potential use in
bioterrorism
(c) 1 listed in OIE/CFSPH
classiﬁcation of pathogens
<Information from the fact sheet>
(c) 2 listed in the Encyclopaedia of
Bioterrorism Defense of Australia
Group
<Information from the fact sheet>
(c) 3 included in any other list of
potential bio- agro-terrorism agents
Question B(v) disease has or could have a signiﬁcant negative impact on the environment,
including biodiversity, of the Union
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(b)(iv) Impact of the
disease on biodiversity
and the environment
(b)(iv) 1 endangered wild species affected:
listed species as in CITES and/or IUCN list
<Information from the fact sheet>
(b)(iv) 2 mortality in wild species <Information from the fact sheet>
(b)(iv) 3 capacity of the pathogen to persist
in the environment and cause mortality in
wildlife
<Information from the fact sheet>
(e)(iv) The impact of
disease prevention and
control measures, as
regards the environment
and biodiversity
(e)(iv) Mortality in wild species <Information from the fact sheet>
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B.3.2. Article 9
Question 1
The answer to the question 1CAq can be Y only for diseases affecting aquatic animal species,
therefore do not assess this question for diseases affecting terrestrial animal species
Questions 2.1
Question 1A the disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present in only in a very limited part of the territory of the
Union
Answer Y ☐ N ☐ na ☐
Question 1B the disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are free of the
disease
Answer Y ☐ N ☐ na ☐
Question 1C the disease is present in the whole OR part of the Union territory with an endemic
character
Answer Y ☐ N ☐ na ☐
Question 1CAq several Member States or zones of the Union are free of the disease
Answer Y ☐ N ☐ na ☐
Mapped Article 7 criteria Mapped Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(b)(i) The impact of the disease on
agricultural and aquaculture
production and other parts of the
economy, as regards level of
presence of the disease in the Union
(b)(i)1 Number of MSs where the
disease is presence
<Information from the fact sheet>
(a)(vii) The absence or presence and
distribution of the disease in the
Union, and, where the disease is not
present in the Union, the risk of its
introduction into the Union
(a)(vii) 1 Map of MSs where the
disease is present
<Information from the fact sheet>
(a)(vii) 2 Type of epidemiological
occurrence
<Information from the fact sheet>
Question 2.1A the disease is highly transmissible
Answer: Y ☐ N ☐ na ☐
Question 2.1BC the disease is moderately to highly transmissible
Answer Y ☐ N ☐ na ☐
Mapped Article 7
criteria
Mapped Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(vi) The routes and
speed of transmission
of the disease between
animals and, when
relevant, between
animals and humans
(a)(vi) 3 Incidence between animals and,
when relevant, between animals and humans
<Information from the fact sheet>
(a)(vi) 4 Transmission rate (beta) (from R0 and
infectious period) between animals and, when
relevant, between animals and humans
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Questions 2.2
Questions 2.3
Question 2.2AB there be possibilities of airborne or waterborne or vector-borne spread
Interpretation – the disease or the infection can be transmitted via airborne or waterborne or vector-borne
(mechanical or biological vector) spread
Answer Y ☐ N ☐ na ☐
Mapped Article 7 criteria
Mapped Article 7
parameters
Assessment of the Article 7
parameters from fact sheet
(a)(vi) The routes and speed of transmission
of the disease between animals and, when
relevant, between animals and humans
(a)(vi) 1 type of routes of
transmission from
animal to animal
(horizontal, vertical)
<Information from the fact sheet>
Question: 2.3A the disease affect multiple species of kept and wild animals OR single species of
kept animals of economic importance
Interpretation – . . .OR at least one single species of kept animals of economic importance
Answer Y ☐ N ☐ na ☐
Mapped Article 7 criteria Mapped Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(i) Animal species concerned
by the disease
(a)(i) 1 naturally susceptible wildlife
species (or families/orders)
<Information from the fact sheet>
(a)(i) 2 naturally susceptible domestic
species (or families/orders)
<Information from the fact sheet>
(a)(i) 3 experimentally susceptible
wildlife species (or families/orders)
<Information from the fact sheet>
(a)(i) 4 experimentally susceptible
domestic species (or families/orders)
(a)(i) 5 wild reservoir species
(or families/orders)
<Information from the fact sheet>
(a)(i) 6 domestic reservoir species
(or families/orders)
<Information from the fact sheet>
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Questions 2.4
The answer to the question 2.4CAq can be Y only for diseases affecting aquatic animal species,
therefore do not assess this question for diseases affecting terrestrial animal species
Questions 3
Question 2.4A the disease may results in high morbidity and signiﬁcant mortality rates
Answer Y ☐ N ☐ na ☐
Question 2.4B the disease may result in high morbidity and in general low mortality
Answer Y ☐ N ☐ na ☐
Question 2.4C the disease usually does not result in high morbidity and has negligible or no
mortality AND often the most observed effect of the disease is production loss
Answer Y ☐ N ☐ na ☐
Question 2.4CAq the disease may result in high morbidity and usually low mortality AND often the
most observed effect of the disease is production loss
Answer Y ☐ N ☐ na ☐
Mapped Article 7 criteria Mapped Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(ii) Morbidity and mortality rates
of the disease in animal populations
(a)(ii) 1 Prevalence/Incidence <Information from the fact sheet>
(a)(ii) 2 Case-morbidity rate <Information from the fact sheet>
(a)(ii) 3 Case-fatality rate <Information from the fact sheet>
(b)(i) Impact of the disease on
agricultural and aquaculture
production and other parts of the
economy
(b)(i) 1 Number of MSs where the
disease is present
<Information from the fact sheet>
(b)(i) 2 Proportion of production
losses (%) by epidemic/endemic
situation (milk, growth, semen,
meat, etc.. . .)
<Information from the fact sheet>
Question 3A the disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
Answer Y ☐ N ☐ na ☐
Question 3B the disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
Answer Y ☐ N ☐ na ☐
Question 3C the disease has a zoonotic potential with signiﬁcant consequences for public health or
possible signiﬁcant threats to food safety
Answer Y ☐ N ☐ na ☐
Mapped Article 7 criteria Mapped Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(a)(iii) Zoonotic character of
the disease
(a)(iii) 1 report of zoonotic human cases <Information from the fact sheet>
(a)(vi) The routes and speed
of transmission of the
disease between animals
and, when relevant,
between animals and
humans
(a)(vi) 2 type of routes of transmission
between animals and humans (direct and
indirect including foodborne)
<Information from the fact sheet>
(a)(vi) 3 Incidence between animals and
when relevant between animals and
humans
<Information from the fact sheet>
(a)(vi) 4 Transmission rate (beta) (from R0
and infectious period) between animals and
when relevant between animals and
humans
(b)(ii) Impact of the disease
on Human health
(b)(ii) 5 Disability-adjusted life year (DALY) <Information from the fact sheet>
(b)(ii) 6 Availability of medical treatment
and their effectiveness (therapeutical effect
and any resistance)
Assessment of animal diseases based on AHL criteria
www.efsa.europa.eu/efsajournal 39 EFSA Journal 2017;15(7):4783
Questions 4
Question 3A the disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
Answer Y ☐ N ☐ na ☐
Question 3B the disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
Answer Y ☐ N ☐ na ☐
Question 3C the disease has a zoonotic potential with signiﬁcant consequences for public health or
possible signiﬁcant threats to food safety
Answer Y ☐ N ☐ na ☐
Mapped Article 7 criteria Mapped Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(b)(ii) 7 Availability of vaccines and their
effectiveness (reduced morbidity)
(c) Potential to generate a
crisis situation and its
Potential use in bioterrorism
(c) 1 listed in OIE/CFSPH classiﬁcation of
pathogens
<Information from the fact sheet>
(c) 2 listed in the Encyclopaedia of
Bioterrorism Defense of Australia Group
<Information from the fact sheet>
(c) 3 included in any other list of potential
bio- agro-terrorism agents
Question 4AB the disease in question has a signiﬁcant impact on the economy of the Union,
causing substantial costs, mainly related to its direct impact on the health and productivity of
animals
Interpretation – due to the substantial costs related to the disease direct impact on the health and productivity
of animals, the disease has a signiﬁcant impact on the economy
Answer current impact Y ☐ N ☐ na ☐
Answer potential impact Y ☐ N ☐ na ☐
Question 4C the disease has a signiﬁcant impact on the economy of the Union, mainly related to
its direct impact on certain types of animal production systems
Interpretation – due to its direct impact on how many types of animal production systems (not related to animal
species but only to the type of products e.g. dairy, beef, reproduction, fattening, etc. and production system:
e.g. indoor, outdoor, organic, etc.), the disease has a signiﬁcant impact on the economy
Answer current impact Y ☐ N ☐ na ☐
Answer potential impact Y ☐ N ☐ na ☐
Mapped Article 7 criteria Mapped Article 7 parameters
Assessment of the Article
7 parameters from fact sheet
(a)(ii) Morbidity and
mortality rates of the disease
in animal populations
(a)(ii) 1 Prevalence/Incidence <Information from the fact sheet>
(a)(ii) 2 Case-morbidity rate (% clinically
diseased animals out of infected ones)
<Information from the fact sheet>
(a)(ii) 3 Case-fatality rate <Information from the fact sheet>
(b)(i) Impact on agricultural
and aquaculture production
and other parts of the
economy
(b)(i) 1 Number of MSs where the disease
is presence
<Information from the fact sheet>
(b)(i) 2 Proportion of production losses (%)
by epidemic/endemic situation (milk,
growth, semen, meat, etc.. . .)
<Information from the fact sheet>
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Questions 5(a)
Questions 5(b)
Questions 5(c)
Question 5(a) the disease has a signiﬁcant impact on society, with in particular an impact on
labour markets
Interpretation- the disease has a signiﬁcant impact on society with (as the most important but not the only one)
an impact on labour markets
Answer current impact Y ☐ N ☐ na ☐
Answer potential impact Y ☐ N ☐ na ☐
Mapped Article 7 criteria Mapped Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(b)(i) Impact on agricultural
and aquaculture production
and other parts of the
economy
(b)(i) 1 Number of MSs where the disease
is presence
<Information from the fact sheet>
(b)(i) 2 Proportion of production losses (%)
by epidemic/endemic situation (milk,
growth, semen, meat, etc.. . .)
<Information from the fact sheet>
Question 5(b) the disease has a signiﬁcant impact on animal welfare, by causing suffering to large
numbers of animals
Interpretation – due to the suffering of large number of animals caused by the disease, the disease has a
signiﬁcant impact on animal welfare
Answer current impact Y ☐ N ☐ na ☐
Answer potential impact Y ☐ N ☐ na ☐
Mapped Article 7 criteria Mapped Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(b)(iii) Impact of the disease on
animal welfare
(b)(iii) 1 severity of clinical signs at
case level and related level and
duration of impairment
<Information from the fact sheet>
(a)(ii) 2 Case-morbidity rate (%
clinically diseased animals out of
infected ones)
<Information from the fact sheet>
Question 5(c) the disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
Interpretation – due to the direct impact of the disease OR to the impact of the measures taken to control it, the
disease has a signiﬁcant impact on the environment
Answer current impact Y ☐ N ☐ na ☐
Answer potential impact Y ☐ N ☐ na ☐
Mapped Article 7 criteria Mapped Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(b)(iv) Impact of the disease
on biodiversity and the
environment
(b)(iv) 1 endangered wild species affected:
listed species as in CITES and/or IUCN list
<Information from the fact sheet>
(b)(iv) 2 Mortality in wild species <Information from the fact sheet>
(e)(iv) The impact of disease
prevention and control
measures
(e)(iv) 1 Mortality in wild species
(e)(iv) 1 use and potential residuals of
biocides or medical drugs in environmental
compartments (soil, water, feed, manure
<Information from the fact sheet>
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Questions 5(d)
Question 5(d) The disease has a signiﬁcant impact on in the long term on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
Interpretation- the consequences of the impact of the disease can even lead to the possible disappearance or
long-term damage of endangered species or breeds
Answer current impact Y ☐ N ☐ na ☐
Answer potential impact Y ☐ N ☐ na ☐
Mapped Article 7 criteria Mapped Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(b)(iv) Impact of the disease
on biodiversity and the
environment
(b)(iv) 1 endangered wild species affected:
listed species as in CITES and/or IUCN list
<Information from the fact sheet>
(b)(iv) 2 Mortality in wild species <Information from the fact sheet>
(b)(iv) 3 Capacity of the pathogen to persist
in the environment and cause mortality in
wildlife
<Information from the fact sheet>
Question D
Question D The risk posed by the disease in question can be effectively and proportionately
mitigated by measures concerning movements of animals and products in order to prevent or limit
its occurrence and spread
Answer Y ☐ N ☐ na ☐
Article 7 criteria Article 7 parameters
Assessment of the Article 7
parameters from fact sheet
(d)(v) Feasibility, availability
and effectiveness of
restrictions on the
movement of animals and
products, as control measure
(d)(v) 1 available restriction movement
measures
<Information from the fact sheet>
(d)(v) 2 effectiveness of restriction of
animal movement in preventing the
between farm spread (description)
<Information from the fact sheet>
(d)(v) 3 feasibility of restriction of animal
movement (description)
<Information from the fact sheet>
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